Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

7.93
Delayed Data
As of Apr 20
 -0.42 / -5.03%
Today’s Change
4.07
Today|||52-Week Range
12.88
-15.55%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$320.5M

Company Description

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company, which is focused on the sales, marketing and development of branded and generic pharmaceutical products for the pediatric market. Its pediatric products are focused on allergy and upper respiratory, including nasal, chest congestion and cough, antibiotics, and dermatology. Pernix Therapeutics Holdings branded products CEDAX, an antibiotic for middle ear infections; NATROBA, which is a topical treatment for head lice; OMECLAMOX-PAK, a ten-day therapy of omeprazole delayed-release capsules, clarithromycin tablets and amoxicillin capsules for the treatment of helicobacter pylori infection and duodenal ulcer disease; and REZYST, which is a probiotic blend to promote dietary management. The company promotes its branded pediatric and generic products through its sales force wholly-owned subsidiary, Macoven Pharmaceuticals. Pernix Therapeutics Holdings was founded in March 9, 2010 and is headquartered in The Woodlands, TX.

Contact Information

Pernix Therapeutics Holdings, Inc.
10 North Park Place
Morristown New Jersey 07960
P:(800) 793-2145
Investor Relations:

Employees

Shareholders

Other institutional56.80%
Individual stakeholders28.33%
Mutual fund holders25.29%

Top Executives

Douglas L. DrysdaleChairman, President & Chief Executive Officer
Terence S. NovakChief Operating Officer
Sanjay S. PatelChief Financial Officer
Michael VentersVice President-Corporate Development
Jessica OienVice President-Compliance

To view my watchlist

Not a member yet?

Sign up now for a free account